Literature DB >> 15461554

Perspectives on cognitive domains, H3 receptor ligands and neurological disease.

Arthur A Hancock1, Gerard B Fox.   

Abstract

Histamine H(3) receptor agonists and antagonists have been evaluated in numerous in vitro and in vivo animal models to better understand how H(3) receptors modulate neurotransmitter function in the central nervous system. Likewise, behavioural models have explored the hypothesis that changes in neurotransmitter release could enhance cognitive function in human diseases. This review examines the reported effects of H(3) receptor ligands and how they influence cognitive behaviour. These data are interpreted on the basis of different cognitive domains that are relevant to neuropsychiatric diseases. Because of the diversity of H(3) receptors, their function and their influence on neurotransmitter systems, considerable promise exists for H(3) ligands to treat diseases in which aspects of learning and memory are impaired. However, because of the complexities of the histaminergic system and H(3) receptors and the lack of clinical data so far, proof of principle for use in human disease remains to be established.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15461554     DOI: 10.1517/13543784.13.10.1237

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  13 in total

1.  Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers.

Authors:  Ahmed A Othman; George Haig; Hana Florian; Charles Locke; Jun Zhang; Sandeep Dutta
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

2.  H3 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing retrieval.

Authors:  Vincent Pascoli; Corinne Boer-Saccomani; Jean-François Hermant
Journal:  Psychopharmacology (Berl)       Date:  2008-05-22       Impact factor: 4.530

Review 3.  The histamine H3 receptor: an attractive target for the treatment of cognitive disorders.

Authors:  T A Esbenshade; K E Browman; R S Bitner; M Strakhova; M D Cowart; J D Brioni
Journal:  Br J Pharmacol       Date:  2008-05-12       Impact factor: 8.739

4.  Central nervous system effects of the histamine-3 receptor antagonist CEP-26401, in comparison with modafinil and donepezil, after a single dose in a cross-over study in healthy volunteers.

Authors:  Anne C Baakman; Rob Zuiker; Joop M A van Gerven; Nicholas Gross; Ronghua Yang; Michael Fetell; Ari Gershon; Yossi Gilgun-Sherki; Edward Hellriegel; Ofer Spiegelstein
Journal:  Br J Clin Pharmacol       Date:  2019-03-14       Impact factor: 4.335

5.  Modulation of prepulse inhibition and stereotypies in rodents: no evidence for antipsychotic-like properties of histamine H3-receptor inverse agonists.

Authors:  Aude Burban; Chit Sadakhom; Dominique Dumoulin; Christiane Rose; Gwenaëlle Le Pen; Henriette Frances; Jean-Michel Arrang
Journal:  Psychopharmacology (Berl)       Date:  2010-05-01       Impact factor: 4.530

Review 6.  The histamine H3 receptor: from discovery to clinical trials with pitolisant.

Authors:  Jean-Charles Schwartz
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

7.  Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo.

Authors:  Marie Humbert-Claude; Elisabeth Davenas; Florence Gbahou; Ludwig Vincent; Jean-Michel Arrang
Journal:  Psychopharmacology (Berl)       Date:  2011-09-13       Impact factor: 4.530

8.  Unexpectedly high affinity of a novel histamine H(3) receptor antagonist, GSK239512, in vivo in human brain, determined using PET.

Authors:  S Ashworth; A Berges; E A Rabiner; A A Wilson; R A Comley; R Y K Lai; R Boardley; G Searle; R N Gunn; M Laruelle; V J Cunningham
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

9.  The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers.

Authors:  Ahmed A Othman; George Haig; Hana Florian; Charles Locke; Lev Gertsik; Sandeep Dutta
Journal:  Br J Clin Pharmacol       Date:  2014-06       Impact factor: 4.335

10.  Characterization of histamine H3 receptors in Alzheimer's Disease brain and amyloid over-expressing TASTPM mice.

Authors:  A D Medhurst; J C Roberts; J Lee; C P L-H Chen; S H Brown; S Roman; M K P Lai
Journal:  Br J Pharmacol       Date:  2009-02-16       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.